Sarepta Therapeutics Statistics
Share Statistics
Sarepta Therapeutics has 98.28M
shares outstanding. The number of shares has increased by 2.65%
in one year.
| Shares Outstanding | 98.28M |
| Shares Change (YoY) | 2.65% |
| Shares Change (QoQ) | 1.58% |
| Owned by Institutions (%) | 93.57% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 7,131 |
| FTD / Avg. Volume | 0.21% |
Short Selling Information
The latest short interest is 6.7M, so 6.82% of the outstanding
shares have been sold short.
| Short Interest | 6.7M |
| Short % of Shares Out | 6.82% |
| Short % of Float | 7.99% |
| Short Ratio (days to cover) | 4.02 |
Valuation Ratios
The PE ratio is 49.14 and the forward
PE ratio is 5.27.
Sarepta Therapeutics's PEG ratio is
-0.35.
| PE Ratio | 49.14 |
| Forward PE | 5.27 |
| PS Ratio | 6.08 |
| Forward PS | 1.2 |
| PB Ratio | 7.57 |
| P/FCF Ratio | -33.73 |
| PEG Ratio | -0.35 |
Financial Ratio HistoryEnterprise Valuation
Sarepta Therapeutics has an Enterprise Value (EV) of 11.8B.
| EV / Sales | 6.2 |
| EV / EBITDA | 35.43 |
| EV / EBIT | -57.34 |
| EV / FCF | -34.43 |
Financial Position
The company has a current ratio of 4.2,
with a Debt / Equity ratio of 0.88.
| Current Ratio | 4.2 |
| Quick Ratio | 3.18 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | 4.03 |
| Debt / FCF | -3.92 |
| Interest Coverage | 11.86 |
Financial Efficiency
Return on Equity is 15.4% and Return on Invested Capital is 6.06%.
| Return on Equity | 15.4% |
| Return on Assets | 5.94% |
| Return on Invested Capital | 6.06% |
| Revenue Per Employee | $1,386,282.07 |
| Profits Per Employee | $171,457 |
| Employee Count | 1,372 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 0.43 |
Taxes
| Income Tax | 25.54M |
| Effective Tax Rate | 9.79% |
Stock Price Statistics
The stock price has increased by -69.16% in the
last 52 weeks. The beta is 0.84, so Sarepta Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.84 |
| 52-Week Price Change | -69.16% |
| 50-Day Moving Average | 56.86 |
| 200-Day Moving Average | 105.39 |
| Relative Strength Index (RSI) | 31.09 |
| Average Volume (20 Days) | 3,422,690 |
Income Statement
In the last 12 months, Sarepta Therapeutics had revenue of 1.9B
and earned 235.24M
in profits. Earnings per share was 2.34.
| Revenue | 1.9B |
| Gross Profit | 1.58B |
| Operating Income | 218.08M |
| Net Income | 235.24M |
| EBITDA | 333.06M |
| EBIT | 279.17M |
| Earnings Per Share (EPS) | 2.34 |
Full Income StatementBalance Sheet
The company has 1.1B in cash and 1.34B in
debt, giving a net cash position of -240.06M.
| Cash & Cash Equivalents | 1.1B |
| Total Debt | 1.34B |
| Net Cash | -240.06M |
| Retained Earnings | -4.21B |
| Total Assets | 3.47B |
| Working Capital | 1.83B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -205.79M
and capital expenditures -136.96M, giving a free cash flow of -342.74M.
| Operating Cash Flow | -205.79M |
| Capital Expenditures | -136.96M |
| Free Cash Flow | -342.74M |
| FCF Per Share | -3.6 |
Full Cash Flow StatementMargins
Gross margin is 83.22%, with operating and profit margins of 11.47% and 12.37%.
| Gross Margin | 83.22% |
| Operating Margin | 11.47% |
| Pretax Margin | 13.71% |
| Profit Margin | 12.37% |
| EBITDA Margin | 17.51% |
| EBIT Margin | 11.47% |
| FCF Margin | -18.02% |
